Advertisement
Research paper| Volume 24, ISSUE 2, P92-97, May 2019

Download started.

Ok

Antimicrobial use in patients at the end of life in an Australian hospital

Published:January 14, 2019DOI:https://doi.org/10.1016/j.idh.2018.12.001

      Highlights

      • There is urgent imperative to optimise antimicrobial use due to increasing resistance.
      • Limited data is available on antimicrobial use in hospital end of life settings.
      • A retrospective study of antibiotic use in patients who died in an Australian hospital.
      • Finding of antibiotic continuation post futility discussion in one third of cases.
      • Clinical, ethical and social considerations complicate antimicrobial use in end of life.

      Abstract

      Background

      Antimicrobial resistance is increasing and there is an urgent international imperative to optimise use within hospitals. Antibiotic use at the end of life is frequent in the hospital setting, but data on use in Australian hospitals in this context is limited, and optimisation is complicated by clinical/diagnostic, ethical and humanistic considerations. As yet there is little data available on baseline use in hospital end of life settings, an empirical gap we sought to begin to fill here.

      Methods

      A retrospective review of antibiotic use in patients who died in a Queensland hospital between January 2015 and July 2015.

      Results

      One hundred and thirty-seven patients were included, of which 73 were male (53.3%) and the median age was 81 years. Of these patients, 86 received antibiotics at the end of life. The most common antibiotic prescribed was piperacillin/tazobactam (41.9%). The most common site of infection was pulmonary (32.8%). Of 86 patients prescribed antibiotics, 29 patients (33.7%) received antibiotics after futility was documented. 83 patients (96.5%) were administered their antibiotics intravenously.

      Conclusion

      Antimicrobial use at the end of life is frequent, with greater than one third of the patients who died in hospital having their antibiotics continued after discussion of futility. Antimicrobial use in this setting is complex with significant clinical, social and ethical considerations which need to be addressed if antibiotic optimization in this area (and more broadly in the hospital) is to be achieved.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Infection, Disease & Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Homsi J.
        • Walsh D.
        • Panta R.
        • Lagman R.
        • Nelson K.A.
        • Longworth D.L.
        Infectious complications of advanced cancer.
        Support Care Cancer. 2000; 8: 487-492
        • Vitetta L.
        • Kenner D.
        • Sali A.
        Bacterial infections in terminally ill hospice patients.
        J Pain Symptom Manag. 2000; 20: 326-334
        • Reinbolt R.E.
        • Shenk A.M.
        • White P.H.
        • Navari R.M.
        Symptomatic treatment of infections in patients with advanced cancer receiving hospice care.
        J Pain Symptom Manag. 2005; 30: 175-182
        • Nakagawa S.
        • Toya Y.
        • Okamoto Y.
        • Tsuneto S.
        • Goya S.
        • Tanimukai H.
        • et al.
        Can anti-infective drugs improve the infection-related symptoms of patients with cancer during the terminal stages of their lives?.
        J Palliat Med. 2010; 13: 535-540
        • Juthani-Mehta M.
        • Malani P.N.
        • Mitchell S.L.
        Antimicrobials at the end of life: an opportunity to improve palliative care and infection management.
        JAMA. 2015; 314: 2017-2018
        • Ford P.J.
        • Fraser T.G.
        • Davis M.P.
        • Kodish E.
        Anti-infective therapy at the end of life: ethical decision-making in hospice-eligible patients.
        Bioethics. 2005; 19: 379-392
        • Marcus E.L.
        • Clarfield A.M.
        • Moses A.E.
        Ethical issues relating to the use of antimicrobial therapy in older adults.
        Clin Infect Dis. 2001; 33: 1697-1705
        • Yao C.A.
        • Hsieh M.Y.
        • Chiu T.Y.
        • Hu W.Y.
        • Hung S.H.
        • Chen C.Y.
        • et al.
        Wishes of patients with terminal cancer and influencing factors toward the use of antibiotics in Taiwan.
        Am J Hosp Palliat Care. 2015; 32: 537-543
        • D'Agata E.
        • Mitchell S.L.
        Patterns of antimicrobial use among nursing home residents with advanced dementia.
        Arch Intern Med. 2008; 168: 357-362
        • Fabiszewski K.J.
        • Volicer B.
        • Volicer L.
        Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients.
        JAMA. 1990; 263: 3168-3172
        • Givens J.L.
        • Jones R.N.
        • Shaffer M.L.
        • Kiely D.K.
        • Mitchell S.L.
        Survival and comfort after treatment of pneumonia in advanced dementia.
        Arch Intern Med. 2010; 170: 1102-1107
        • Mitchell S.L.
        • Shaffer M.L.
        • Loeb M.B.
        • Givens J.L.
        • Habtemariam D.
        • Kiely D.K.
        • et al.
        Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia.
        JAMA Intern Med. 2014; 174: 1660-1667
        • Servid S.A.
        • Noble B.N.
        • Fromme E.K.
        • Furuno J.P.
        Clinical intentions of antibiotics prescribed upon discharge to hospice care.
        J Am Geriatr Soc. 2018; 66: 565-569
        • Chih A.H.
        • Lee L.T.
        • Cheng S.Y.
        • Yao C.A.
        • Hu W.Y.
        • Chen C.Y.
        • et al.
        Is it appropriate to withdraw antibiotics in terminal patients with cancer with infection?.
        J Palliat Med. 2013; 16: 1417-1422
        • Cheng H.W.
        • Sham M.K.
        • Chan K.Y.
        Emergence of vancomycin-resistant enterococci in the palliative care setting-how to strike the right balance in infection control measures?.
        J Pain Symptom Manag. 2014; 47: e7-e8
        • Pautex S.
        • Vayne-Bossert P.
        • Jamme S.
        • Herrmann F.
        • Vilarino R.
        • Weber C.
        • et al.
        Anatomopathological causes of death in patients with advanced cancer: association with the use of anticoagulation and antibiotics at the end of life.
        J Palliat Med. 2013; 16: 669-674
        • Nagy-Agren S.
        • Haley H.
        Management of infections in palliative care patients with advanced cancer.
        J Pain Symptom Manag. 2002; 24: 64-70
        • White P.H.
        • Kuhlenschmidt H.L.
        • Vancura B.G.
        • Navari R.M.
        Antimicrobial use in patients with advanced cancer receiving hospice care.
        J Pain Symptom Manag. 2003; 25: 438-443
        • Oh D.Y.
        • Kim J.H.
        • Kim D.W.
        • Im S.A.
        • Kim T.Y.
        • Heo D.S.
        • et al.
        Antibiotic use during the last days of life in cancer patients.
        Eur J Cancer Care (Engl). 2006; 15: 74-79
        • Mirhosseini M.
        • Oneschuk D.
        • Hunter B.
        • Hanson J.
        • Quan H.
        • Amigo P.
        The role of antibiotics in the management of infection-related symptoms in advanced cancer patients.
        J Palliat Care. 2006; 22: 69-74
        • Thompson A.J.
        • Silveira M.J.
        • Vitale C.A.
        • Malani P.N.
        Antimicrobial use at the end of life among hospitalized patients with advanced cancer.
        Am J Hosp Palliat Care. 2012; 29: 599-603
        • Lam P.T.
        • Chan K.S.
        • Tse C.Y.
        • Leung M.W.
        Retrospective analysis of antibiotic use and survival in advanced cancer patients with infections.
        J Pain Symptom Manag. 2005; 30: 536-543
        • Thai V.
        • Lau F.
        • Wolch G.
        • Yang J.
        • Quan H.
        • Fassbender K.
        Impact of infections on the survival of hospitalized advanced cancer patients.
        J Pain Symptom Manag. 2012; 43: 549-557
        • Albrecht J.S.
        • McGregor J.C.
        • Fromme E.K.
        • Bearden D.T.
        • Furuno J.P.
        A nationwide analysis of antibiotic use in hospice care in the final week of life.
        J Pain Symptom Manag. 2013; 46: 483-490
        • Chen L.K.
        • Chou Y.C.
        • Hsu P.S.
        • Tsai S.T.
        • Hwang S.J.
        • Wu B.Y.
        • et al.
        Antibiotic prescription for fever episodes in hospice patients.
        Support Care Cancer. 2002; 10: 538-541
        • Novak R.L.
        • Noble B.N.
        • Fromme E.K.
        • Tice M.O.
        • McGregor J.C.
        • Furuno J.P.
        Antibiotic policies and utilization in Oregon hospice programs.
        Am J Hosp Palliat Care. 2016; 33: 777-781
        • Abduh Al-Shaqi M.
        • Alami A.H.
        • Zahrani A.S.
        • Al-Marshad B.
        • Muammar A.B.
        • M Z.A.
        The pattern of antimicrobial use for palliative care in-patients during the last week of life.
        Am J Hosp Palliat Care. 2012; 29: 60-63
        • Clayton J.
        • Fardell B.
        • Hutton-Potts J.
        • Webb D.
        • Chye R.
        Parenteral antibiotics in a palliative care unit: prospective analysis of current practice.
        Palliat Med. 2003; 17: 44-48
        • Pereira J.
        • Watanabe S.
        • Wolch G.
        A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit.
        J Pain Symptom Manag. 1998; 16: 374-381
        • Merel S.E.
        • Meier C.A.
        • McKinney C.M.
        • Pottinger P.S.
        Antimicrobial use in patients on a comfort care protocol: a retrospective cohort study.
        J Palliat Med. 2016; 19: 1210-1214
        • Rosenberg J.H.
        • Albrecht J.S.
        • Fromme E.K.
        • Noble B.N.
        • McGregor J.C.
        • Comer A.C.
        • et al.
        Antimicrobial use for symptom management in patients receiving hospice and palliative care: a systematic review.
        J Palliat Med. 2013; 16: 1568-1574
        • Hickman S.E.
        • Nelson C.A.
        • Moss A.H.
        • Tolle S.W.
        • Perrin N.A.
        • Hammes B.J.
        The consistency between treatments provided to nursing facility residents and orders on the physician orders for life-sustaining treatment form.
        J Am Geriatr Soc. 2011; 59: 2091-2099
        • Stiel S.
        • Krumm N.
        • Pestinger M.
        • Lindena G.
        • Nauck F.
        • Ostgathe C.
        • et al.
        Antibiotics in palliative medicine--results from a prospective epidemiological investigation from the HOPE survey.
        Support Care Cancer. 2012; 20: 325-333
        • Oneschuk D.
        • Fainsinger R.
        • Demoissac D.
        Antibiotic use in the last week of life in three different palliative care settings.
        J Palliat Care. 2002; 18: 25-28
        • Levin P.D.
        • Simor A.E.
        • Moses A.E.
        • Sprung C.L.
        End-of-life treatment and bacterial antibiotic resistance: a potential association.
        Chest. 2010; 138: 588-594
        • Kwak Y.G.
        • Moon C.
        • Kim E.S.
        • Kim B.N.
        Frequent prescription of antibiotics and high burden of antibiotic resistance among deceased patients in general medical wards of acute care hospitals in Korea.
        PLoS One. 2016; 11e0146852
        • Datta R.
        • Juthani-Mehta M.
        Burden and management of multidrug-resistant organisms in palliative care.
        Palliat Care. 2017; 10 (1178224217749233)
        • Datta R.
        • Shah A.
        • Huang S.S.
        • Cui E.
        • Nguyen V.
        • Welbourne S.J.
        • et al.
        High nasal burden of methicillin-resistant Staphylococcus aureus increases risk of invasive disease.
        J Clin Microbiol. 2014; 52: 312-314
        • Chun E.D.
        • Rodgers P.E.
        • Vitale C.A.
        • Collins C.D.
        • Malani P.N.
        Antimicrobial use among patients receiving palliative care consultation.
        Am J Hosp Palliat Care. 2010; 27: 261-265
        • Cardona-Morrell M.
        • Kim J.
        • Turner R.M.
        • Anstey M.
        • Mitchell I.A.
        • Hillman K.
        Non-beneficial treatments in hospital at the end of life: a systematic review on extent of the problem.
        Int J Qual Health Care. 2016; 28: 456-469
        • Gaw C.E.
        • Hamilton K.W.
        • Gerber J.S.
        • Szymczak J.E.
        Physician perceptions regarding antimicrobial use in end-of-life care.
        Infect Control Hosp Epidemiol. 2018; 39: 383-390
        • Baghban A.
        • Juthani-Mehta M.
        Antimicrobial use at the end of life.
        Infect Dis Clin N Am. 2017; 31: 639-647